Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study

TitleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled study
Authors
KeywordsAzithromycin
Bronchiolitis obliterans syndrome (BOS)
Hematopoietic SCT (HSCT)
Issue Date2011
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556 How to Cite?
AbstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.
Persistent Identifierhttp://hdl.handle.net/10722/139447
ISSN
2014 Impact Factor: 3.570
2013 SCImago Journal Rankings: 1.441
ISI Accession Number ID
Funding AgencyGrant Number
Pfizer Pharmaceuticals
Funding Information:

This study and the drug used in this study were sponsored by Pfizer Pharmaceuticals.

References

 

DC FieldValueLanguage
dc.contributor.authorLam, CLDen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorWong, MKYen_HK
dc.contributor.authorLu, Cen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorTse, EWCen_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLiang, RHSen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorIp, MSMen_HK
dc.contributor.authorLie, AKWen_HK
dc.date.accessioned2011-09-23T05:50:01Z-
dc.date.available2011-09-23T05:50:01Z-
dc.date.issued2011en_HK
dc.identifier.citationBone Marrow Transplantation, 2011, v. 46 n. 12, p. 1551-1556en_HK
dc.identifier.issn0268-3369en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139447-
dc.description.abstractBronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n10) received oral azithromycin 250 mg daily while the control group (n12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV 1). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV 1 measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study. © 2011 Macmillan Publishers Limited.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_HK
dc.relation.ispartofBone Marrow Transplantationen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAzithromycinen_HK
dc.subjectBronchiolitis obliterans syndrome (BOS)en_HK
dc.subjectHematopoietic SCT (HSCT)en_HK
dc.titleEffects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCTa randomized double-blinded placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.emailTse, EWC:ewctse@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, RHS:rliang@hku.hken_HK
dc.identifier.emailIp, MSM:msmip@hku.hken_HK
dc.identifier.authorityTse, EWC=rp00471en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, RHS=rp00345en_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1038/bmt.2011.1en_HK
dc.identifier.pmid21317934-
dc.identifier.scopuseid_2-s2.0-84856096516en_HK
dc.identifier.hkuros193943en_US
dc.identifier.hkuros193942en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84856096516&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume46en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1551en_HK
dc.identifier.epage1556en_HK
dc.identifier.isiWOS:000298326500009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, DCL=54913779400en_HK
dc.identifier.scopusauthoridLam, B=9246012800en_HK
dc.identifier.scopusauthoridWong, MKY=23480818200en_HK
dc.identifier.scopusauthoridLu, C=36013065000en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridTse, EWC=7005019454en_HK
dc.identifier.scopusauthoridLeung, AYH=55091367300en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLiang, RHS=26643224900en_HK
dc.identifier.scopusauthoridLam, WK=35934675100en_HK
dc.identifier.scopusauthoridIp, MSM=7102423259en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.citeulike8819673-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats